The venture will focus on the use of the recombinant laminin 511E8 fragment which was developed by Kyoto University iPS Cell Research members and is now marketed by Nippi, a collagen product company. Matrixome will develop various equipment coated with this laminin derivative for use in cell culture technology.

Nippi news release, February 1, 2016